Osaka, Japan

Iwao Takamuro


Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2008-2014

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Iwao Takamuro: Innovator in Arylalkylamine Compounds

Introduction

Iwao Takamuro is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of arylalkylamine compounds. With a total of 7 patents to his name, Takamuro's work has had a notable impact on medical science.

Latest Patents

Takamuro's latest patents include innovative compounds and processes for preparing arylalkylamine compounds. One of his notable inventions is an arylalkylamine compound represented by a specific formula, which can also exist as a pharmaceutically acceptable salt. This compound is recognized for its potential use as an activating compound (CaSR agonist) of a calcium-sensing receptor. Additionally, he has developed a pharmaceutical composition that incorporates this compound as an effective ingredient.

Career Highlights

Iwao Takamuro is currently associated with Mitsubishi Tanabe Pharma Corporation, where he continues to advance his research and development efforts. His work has been instrumental in enhancing the understanding and application of arylalkylamine compounds in the pharmaceutical industry.

Collaborations

Takamuro has collaborated with notable colleagues, including Hiroshi Miyazaki and Kosuke Yasuda, to further his research initiatives. Their combined expertise has contributed to the successful development of innovative pharmaceutical solutions.

Conclusion

Iwao Takamuro's contributions to the field of pharmaceuticals, particularly through his patents on arylalkylamine compounds, highlight his role as a key innovator. His ongoing work at Mitsubishi Tanabe Pharma Corporation continues to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…